Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type

NCT04127227 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

NK/T Cell Lymphoma Nos

Interventions

DRUG: sintilimab,pegaspargase,gemcitabine,oxaliplatin

Sponsor

Sun Yat-sen University